cHER2 + VEGFR2 targeting vaccine (Listeria vector) (Advaxis)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NamecHER2 + VEGFR2 targeting vaccine (Listeria vector) (Advaxis)

Drug Alias NameN/A

ClassificationVaccines > Development/production technology > Live attenuated vaccineVaccines > Development/production technology > Recombinant vector vaccine

Mechanisms of ActionVascular endothelial growth factor receptor 2 antagonistsReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsVascular endothelial growth factor receptor 2Receptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesAyala Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAyala Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A